ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280,037,058 | -28.9% | 13,959,973 | 0.0% | 3.36% | -26.6% |
| Q2 2023 | $393,810,838 | +148.9% | 13,959,973 | +51.7% | 4.58% | +112.9% |
| Q1 2023 | $158,239,536 | -14.6% | 9,199,973 | 0.0% | 2.15% | -39.2% |
| Q4 2022 | $185,287,456 | -7.0% | 9,199,973 | 0.0% | 3.54% | -7.2% |
| Q3 2022 | $199,271,000 | -22.9% | 9,199,973 | 0.0% | 3.81% | -34.9% |
| Q2 2022 | $258,519,000 | +28.8% | 9,199,973 | +111.5% | 5.86% | +143.2% |
| Q1 2022 | $200,676,000 | -45.1% | 4,349,279 | 0.0% | 2.41% | -40.8% |
| Q4 2021 | $365,600,000 | +26.1% | 4,349,279 | 0.0% | 4.07% | +23.4% |
| Q3 2021 | $289,836,000 | +32.9% | 4,349,279 | +6.1% | 3.30% | +38.4% |
| Q2 2021 | $218,159,000 | +31.6% | 4,100,739 | +7.3% | 2.38% | +24.4% |
| Q1 2021 | $165,825,000 | -16.5% | 3,821,739 | 0.0% | 1.92% | -10.8% |
| Q4 2020 | $198,501,000 | +58.9% | 3,821,739 | 0.0% | 2.15% | +29.3% |
| Q3 2020 | $124,933,000 | -31.9% | 3,821,739 | 0.0% | 1.66% | -42.0% |
| Q2 2020 | $183,520,000 | – | 3,821,739 | – | 2.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |